510(k) Report

510(k) · Cleared

Cleared

Alere BinaxNOW Influenza A & B Card 2, Alere Reader, Alere BinaxNOW Influenza A & B Card 2 Control Swab Kit

K162642510(k) TraditionalCleared Apr 10, 2017200-day reviewClass II21 CFR 866.3328

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Alere Scarborough, Inc. · PSZ Devices Detecting Influenza A, B, And C Virus Antigens

Cleared on Apr 10, 2017 as substantially equivalent to K160161 (Becton, Dickinson & CO, 2016) after a 200-day review. Its family tree reaches back 12 generations to 1990. 2 later devices descend from it.

Decided
Apr 10, 2017
Review
200 days
Class
Class II
Product code
PSZ
Recalls
None
Predicates
1

Its longest line of descent runs back 12 generations to K902609 (1990). 14 ancestors in all. 2 later devices descend from it, 1 citing it directly.

  1. Root · 12 generations backK902609 Directigen Flu aBd Becton Dickinson Vacutainer Systems Preanalytic · 1990
  2. 8 generations between
  3. 3 generations backK151291 BD Veritor (TM) System for the Rapid Detection of Flu A+BBecton, Dickinson and Company · 2015
  4. 2 generations backK152870 BD Veritor System for the Rapid Detection of Flu A + B CLIA waived kitBecton, Dickinson and Co. · 2015
  5. 1 generation backK160161 BD Veritor System for Rapid Detection of Flu A + B CLIA waived kitBecton, Dickinson & CO · 2016
  6. This deviceK162642 Alere BinaxNOW Influenza A & B Card 2, Alere Reader, Alere BinaxNOW…Alere Scarborough, Inc. · 2017
  7. Descendant · cites it directly · 1 of its ownK173502 Alere BinaxNOW Influenza A & B Card 2, Alere Reader, Alere BinaxNOW…Alere Scarborough, Inc. · 2017
  8. Descendant · 2 generations on · 0 of its ownK181853 Alere BinaxNOW Influenza A & B Card 2, Alere ReaderAlere Scarborough, Inc. · 2018
Show all 12 generations
  1. Root · 12 generations backK902609 Directigen Flu aBd Becton Dickinson Vacutainer Systems Preanalytic · 1990
  2. 11 generations backK981651 AB Flu OiaBiostar, Inc. · 1998
  3. 10 generations backK023556 Flu Oia a/B Test KitThermo Biostar, Inc. · 2003 · Recalled
  4. 9 generations backK031899 Quickvue Influenza a+B TestQuidel Corp. · 2003
  5. 8 generations backK053146 Quickvue Influenza a + B TestQuidel Corp. · 2005
  6. 7 generations backK092698 Quickvue Influenza a+B TestQuidel Corp. · 2009
  7. 6 generations backK112277 BD Veritor (TM) System for Rapid Detection of Flu a+BBecton, Dickinson and Company · 2011 · Recalled
  8. 5 generations backK132259 BD Veritor System for the Rapid Detection of Flu a+BBecton, Dickinson and Company · 2013
  9. 4 generations backK132692 BD Veritor System for the Rapid Detection of Flu a+BBecton, Dickinson and Company · 2013
  10. 3 generations backK151291 BD Veritor (TM) System for the Rapid Detection of Flu A+BBecton, Dickinson and Company · 2015
  11. 2 generations backK152870 BD Veritor System for the Rapid Detection of Flu A + B CLIA waived kitBecton, Dickinson and Co. · 2015
  12. 1 generation backK160161 BD Veritor System for Rapid Detection of Flu A + B CLIA waived kitBecton, Dickinson & CO · 2016
  13. This deviceK162642 Alere BinaxNOW Influenza A & B Card 2, Alere Reader, Alere BinaxNOW…Alere Scarborough, Inc. · 2017

Most influential descendants

Showing 2 of 2 · See all
  • K173502Alere BinaxNOW Influenza A & B Card 2, Alere Reader, Alere BinaxNOW Influenza A & B Card…Alere Scarborough, Inc. · 2017 · cites it directly1descendant
  • K181853Alere BinaxNOW Influenza A & B Card 2, Alere ReaderAlere Scarborough, Inc. · 2018 · 2 generations on0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−12K902609Directigen Flu aBd Becton Dickinson Vacutainer Systems Preanalytic1990—
−11K981651AB Flu OiaBiostar, Inc.1998—
−10K023556Flu Oia a/B Test KitThermo Biostar, Inc.20031
−9K031899Quickvue Influenza a+B TestQuidel Corp.2003—
−8K053146Quickvue Influenza a + B TestQuidel Corp.2005—
−7K092698Quickvue Influenza a+B TestQuidel Corp.2009—
−6K112277BD Veritor (TM) System for Rapid Detection of Flu a+BBecton, Dickinson and Company20111
−5K132259BD Veritor System for the Rapid Detection of Flu a+BBecton, Dickinson and Company2013—
−4K132692BD Veritor System for the Rapid Detection of Flu a+BBecton, Dickinson and Company2013—
−3K151291BD Veritor (TM) System for the Rapid Detection of Flu A+BBecton, Dickinson and Company2015—
−2K152870BD Veritor System for the Rapid Detection of Flu A + B CLIA waived kitBecton, Dickinson and Co.2015—
−1K160161BD Veritor System for Rapid Detection of Flu A + B CLIA waived kitBecton, Dickinson & CO2016—
0 (this device)K162642Alere BinaxNOW Influenza A & B Card 2, Alere Reader, Alere BinaxNOW Influenza…Alere Scarborough, Inc.2017—
+1K173502Alere BinaxNOW Influenza A & B Card 2, Alere Reader, Alere BinaxNOW Influenza…Alere Scarborough, Inc.2017—
+2K181853Alere BinaxNOW Influenza A & B Card 2, Alere ReaderAlere Scarborough, Inc.2018—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
199910
200010

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201710
201810
FIG. 1 — Lineage of K162642, 1990–2018Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in PSZ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new PSZ device

  1. #1 K252283 Nano-Check Influenza A+B Testscore 14.9 · 15 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K160161BD Veritor System for Rapid Detection of Flu A + B CLIA waived kit
Summary page 5
…REVISED 510(K) SUMMARY PREDICATE DEVICE BD Veritor System for Rapid Detection of Flu A+B, K160161. DEVICE DESCRIPTION The Alere BinaxNOW® Influenza A & B Card 2 is an immunochromatographic membrane assay that detects influenz…
Becton, Dickinson & CO2016—

Also cleared against K160161: 2 other devices →

What descends from it? (2)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K173502Alere BinaxNOW Influenza A & B Card 2, Alere Reader, Alere BinaxNOW Influenza A & B Card…Alere Scarborough, Inc.20171

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 27 years and passes through 8 companies; a new generation was cleared every 1.8 years on median.
  • 2 of the 14 ancestors have a recall of any class.
  • Of its descendants, K173502 (Alere Scarborough, Inc., 2017) has gone furthest, with 1 descendant of its own.
  • 2 other devices also cite its predicate K160161.

How does its category compare?

All PSZ devices

PSZ Devices Detecting Influenza A, B, And C Virus Antigens: FDA decisions, review times, recalls and adverse event reports over 20 years. 2017, this device’s year, is highlighted.

FDA decisions per year · PSZ

2in 2025

2007: 22008: 12009: 72010: 52011: 32012: 22013: 82014: 12015: 42016: 32017: 32018: 52020: 22023: 22025: 22026 (partial year): 2
2007high 8 (2013) · low 0 (2019)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · PSZ

28in 2018

2009: 20 days median2010: 29 days median2011: 80 days median2013: 28 days median2015: 27 days median2016: 29 days median2017: 200 days median2018: 28 days median
2007high 200 (2017) · low 20 (2009)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · PSZ

1in 2022

2020: 12022: 1
2007high 1 (2020) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · PSZ

60in 2025

2018: 12019: 12020: 52021: 422022: 102023: 122024: 162025: 60
2007high 60 (2025) · low 0 (2007)2025

MAUDE reports naming product code PSZ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—00
20081—00
200972000
201052900
201138000
20122—00
201382800
20141—00
201542700
201632900
2017320000
201852801
20190—01
20202—15
20210—042
20220—110
20232—012
20240—016
20252—060
20262—0—

What is it indicated for?

The Alere BinaxNOW® Influenza A & B Card 2 is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal swab specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results are presumptive and should be confirmed by cell culture or an FDA-cleared influenza A and B molecular assay. Negative test…

Read the full statement (217 words)

The Alere BinaxNOW® Influenza A & B Card 2 is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal swab specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results are presumptive and should be confirmed by cell culture or an FDA-cleared influenza A and B molecular assay. Negative test results do not preclude influenza viral infection and should not be used as the sole basis for treatment or other patient management decisions.

Alere BinaxNOW® Influenza A & B Card 2 must be read by the Alere™ Reader.

Performance characteristics for influenza A were established during the 2015-2016 influenza season when influenza A/H3N2 and A/H1N1 pandemic were the predominant influenza A viruses in circulation. When other influenza A viruses are emerging, performance characteristics may vary.

If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent Influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K162642: Alere BinaxNOW Influenza A & B Card 2, Alere Reader, Alere BinaxNOW Influenza A & B Card 2 Control Swab Kit.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K162642

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026